Phase 2 Multicenter, Randomized, Controlled Study of NTX-001 versus Standard of Care in Treatment and Prevention of Facial Paralysis Requiring Surgical Repair
Latest Information Update: 26 Jul 2022
At a glance
- Drugs NTX-001 Neuraptive Therapeutics (Primary)
- Indications Facial paralysis
- Focus Adverse reactions; Therapeutic Use
- 21 Jul 2022 According to a Neuraptive Therapeutics media release, first patient has been enrolled.
- 21 Jul 2022 Status changed from planning to recruiting, according to a Neuraptive Therapeutics media release.
- 14 Apr 2021 New trial record